Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butoconazole is an imidazole antifungal agent primarily used as a vaginal cream for the local treatment of vulvovaginal candidiasis (yeast infections) caused by *Candida albicans*. It works by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes. This is achieved through inhibition of the enzyme lanosterol 14-alpha demethylase (a cytochrome P450 enzyme), leading to altered membrane permeability and ultimately growth inhibition or death of the fungus[4][6][8]. Butoconazole may also exhibit some antibacterial activity against gram-positive organisms. The drug is approved for use in adults and has demonstrated clinical efficacy in treating vaginal yeast infections[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butoconazole.